key: cord-0732406-bcu494jl
authors: Grieco, Teresa; Chello, Camilla; Sernicola, Alvise; Muharremi, Rovena; Michelini, Simone; Paolino, Giovanni; Carnicelli, Giorgia; Pigatto, Paolo Daniele
title: How does COVID-19 impact atopic dermatitis patients in dupilumab therapy? An investigative online survey
date: 2021-07-17
journal: Clin Dermatol
DOI: 10.1016/j.clindermatol.2021.07.008
sha: fdd80447c902a429dc8cc23197756936ecea84f3
doc_id: 732406
cord_uid: bcu494jl

Data on the tolerability and response to biologic therapies for type 2 immune disorders in the context of COVID-19 is currently lacking. Our survey aimed at assessing the adherence of patients to dupilumab therapy and the risk of SARS-CoV-2 infection. 80 subjects with atopic dermatitis treated with dupilumab completed a web-based survey. Seven subjects discontinued dupilumab due to concerns and difficulties related to COVID-19. Our sample was highly susceptible to viral infection due to the frequency of risk factors including living in high SARS-CoV-2 burden areas – such as Northern Italy –, comorbidities – asthma, diabetes and cardiovascular disease – and advanced age. Elderly subjects in our sample are particularly exposed to the risk of COVID-19-related cytokine storm, triggered by excessive IL-4 production and type 2 immune response. One patient contracted SARS-CoV-2 infection without progression of COVID-19 despite continuing scheduled dupilumab treatment. Because evidence on the appropriate management of biologic therapy in the setting of COVID-19 is lacking, the collection of clinical data from patients in treatment with dupilumab is a valuable addition to current clinical practice. Our survey provides a contribution to the understanding of the tolerability and response to dupilumab during COVID-19 and suggests a feasible and effective approach to patients in treatment with biologics even when social distancing is required.

Dupilumab, an anti-IL-4/IL-13 humanized monoclonal antibody, is the first biologic treatment approved by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) in 2017 for the treatment of moderate-to-severe atopic dermatitis (AD) in patients who are candidates for systemic therapy. 1 2,3 The drug is a powerful suppressor of type 2 cytokine production, being an inhibitor of IL-4/IL-13 receptors. 4 It is also currently being evaluated for its potential application in other allergic diseases, including asthma 5 and chronic rhinosinusitis with nasal polyps. 6 Owing to its high rate of contagion and the shocking rate of spread, SARS-CoV-2 infection has raised worldwide concern about the use of biological therapies during the pandemic. 7 There has been a lack of knowledge about the possible interference of immune modulating drugs with the COVID-19 associated cytokine storm and their potential role in promoting viral replication and lethality. 8 The many restrictions on interpersonal contacts, especially in medical practice, have created a significant problem for the management and follow-up of patients receiving biologics.

The use of biologic drugs selectively targeting type 2 inflammatory mediators may be considered safe in the current epidemic setting: the European Task Force on Atopic Dermatitis (ETFAD) recently stated that "targeted treatment selectively interfering with type-2 inflammation such as dupilumab is not considered to increase the risk for viral infections." This is contrary to traditional immunosuppressive therapies, including cyclosporine and methotrexate, that should be avoided in the COVID-19 era. 9 According to the evidence gathered to date from clinical studies, biologic immunomodulating therapies should not be discontinued, in spite of COVID-19 infectivity; 10 however, the role of these therapies during the current pandemic is yet to be clarified, and further real-life data must be collected. 11 Compounding the problem are the current restrictions placed on healthcare facilities: hospitals are considered a possible source of infection, therefore the number of accesses and procedures performed has been reduced dramatically. It can be a challenge for physicians to promote therapeutic continuity in patients suffering from chronic disorders and at the same time to minimize hospital exposure. A strategy to address the issue is teledermatology.

The aim of our study was to investigate the patient's perspective on dupilumab treatment in the setting of COVID-19, using a purposely designed online survey. The questionnaire addressed the effects of COVID-19 on the management of treatment. Each patient was provided information about adherence to dupilumab therapy and activity of AD, as to improvement, worsening, or stability. These data allowed us to assess the quality of life of patients and their tolerability to dupilumab during the COVID-19 epidemic. All patients receiving dupilumab during the lockdown period, lasting from the February 3 rd to May 29 th , 2020, were approached in the course of a routine teleconsultation and asked to complete the survey. Patients who provided consent were given a link to the online survey.

Each patient was given the same online questionnaire (Google forms; Google LLC; Menlo Park, California, USA) in Italian; all answers were self-reported. No personal data, such as name, e-mail address, or IP address, were requested in order to preserve the anonymity of patients. No patient received remuneration for participating in the study.

The questionnaire investigated the following aspects: demographic characteristics including age, sex, and residence; clinical characteristics including personal history focused on risk factors for COVID-19; recent flu-like symptoms; and management of dupilumab therapy during national lockdown.

Data were visually inspected for potential confounders, before any statistical analysis was performed. Descriptive statistics was performed: quantitative variables were expressed as median [range] or mean ± standard deviation, as appropriate; qualitative variables were described as frequency and percentage. Patient reported outcomes were expressed using a numeric rating scale (NRS) collected at monthly intervals (T1 = February; T2= March; T3 = April). Outcomes at T1 and T3 were compared by using Wilcoxon signed-rank test, a nonparametric test for comparing two related samples. Measurements at T1-T2-T3 were compared by using Friedman test, a non-parametric statistical test that detects eventual differences across serial measurements. A value of p<0.05 was considered statistically significant.

We enrolled 80 patients in the study, 39 men (50,7%) and 41 women (49,20%), with a median age of 31.5 years (18 -89 years). Of the 80 enrolled patients, 59 completed the online questionnaire with a response rate of 73.8%. Our sample was representative of both higher and lower risk regions in Italy, as 12 patients (15%) lived in such high-risk areas as Veneto and Lombardy, while 56 patients lived in the lower risk area of Lazio. Eleven patients reported direct exposure to COVID-19 infection, following contact with acquaintances, relatives, and coworkers in 6, 3 and 2 cases testing positive, respectively. 40 subjects (57,1%) complained with at least one comorbidity associated with increased susceptibility to SARS-CoV-2. 36 (45%) patients were diagnosed with asthma, which is associated with up to 35-45% cases of AD as well as with increased susceptibility to viral respiratory infection. 12 Six patients (7.5%) suffered from cardiovascular disease, one from diabetes mellitus, and one with a history of pneumonia. Only 8 patients (10%) received seasonal flu vaccine.

We also monitored adherence to the therapeutic protocol. 73 patients continued receiving dupilumab at the standard dosing every two weeks: all of them had a positive response to treatment and did not suffer from any complication or concomitant disease. Seven patients interrupted treatment, five due to personal concerns, one due to difficulty in retrieving the drug, and one following recommendations of a physician. In the course of monthly telephone contacts, all patients were asked to report the intensity of pruritus, of sleep disturbances related to AD, and the perceived severity of cutaneous lesions.

Patient reported outcomes were measured using NRS at monthly intervals (T1= February; T2= March; T3 = April) to highlight trends associated to a change in disease (Table 1) . No statistically significant differences between outcomes at T1 and T3 was shown with Wilcoxon signed-rank test for pruritus score (p = 0.4654), sleep symptoms (p = 0.88076), or lesion severity score (p = 0.19706). No statistically significant differences across T1-T2-T3 were shown with Friedman test for repeated measures for pruritus score (p = 0.62189), sleep symptoms (p = 0.72253) and lesion severity score (p = 0.18731).

Only seven (8.8%) patients in our sample complained of flu-like symptoms, despite their unfavorable risk profile characterized by: comorbidities associated with increased susceptibility to viral respiratory infection, travel within high-risk areas, or potential exposure to SARS-CoV-2. The symptoms resolved within one week in five patients, while in two subjects they lasted either up to two weeks or over two weeks. The latter two cases were associated with a high fever > 37.5 ° C. Additionally, three patients (3.8%) were subjected to quarantine, while three underwent nasopharyngeal swab for virus RNA, with one positive result. Patient characteristics and examination variables are described in Table 2 .

Dupilumab is a human IgG monoclonal antibody directed against the alpha subunit of IL-4R:

its binding restricts signaling induced by IL-4 and IL-13, key cytokines of type 2 inflammation and fundamental players in the pathogenesis of AD. These cytokines are able to downregulate the expression of epidermal barrier genes contributing to epidermal barrier disruption. IL-4 and IL-13 are known to enhance the release of proinflammatory cytokines, histamine and other potent mediators of inflammation. 13 Finally, activation of IL-4/IL-13 receptor and histamine receptors on nerve fibers, is responsible for the enhanced sensation of pruritus due to hyper-activation of dermal sensory nervous fibers. 14 The immune-pathogenesis of SARS-CoV-2 recognizes several proinflammatory cytokines, such as IL-6, TNF, IL-1beta, and IL-17, each a known contributor to the COVID-19-related cytokine storm, the ultimate cause of multi organ failure and death in the majority of COVID-19 patients. 15 Interferon production seems to be downregulated in COVID-19 infection, as a mechanism to delay clearance of the virus from the organism. 16 Hypothetically, the use of biologics that are highly selective for a single cytokine, such as anti-IL-6 tocilizumab or anti IL-1beta anakinra, could constitute a potential therapeutic option in the treatment of COVID-19. 17 Recent evidence in the literature has highlighted that dupilumab does not worsen the clinical condition in subjects with SARS-CoV-2 infection, possibly owing to the neutralization of specific inflammatory mediators rather than broad immunosuppression. 18 A recent study investigated the potential role of dupilumab in positively modulating the inflammatory response in advanced COVID-19 infection: IL-4 is hypothesized to be a major driver of the cytokine storm, especially in the elderly, and of the fatal hemophagocytic lymphohistiocytosis syndrome. IL-4 is universally known for its role in inflammatory lung diseases including asthma and some endotypes of chronic obstructive pulmonary disease. 19 Additionally, patients with AD frequently suffer from asthma and rhinosinusitis: dupilumab was recently approved for the treatment of severe type 2 asthma that cannot be controlled with previous-line drugs. In this setting, dupilumab could protect not only from the risk of an asthmatic exacerbation, but it could also reduce the susceptibility to severe respiratory infection. 20 These hypotheses are highly attractive, as they could support the use of already approved agents in the management of COVID-19, for which specific treatment is not yet available.

Such proposed mechanisms of action partially explain the safety profile of dupilumab and the success of therapy during the current pandemic. Knowledge about the role of dupilumab in individuals exposed to COVID-19 remains largely lacking. 21, 22 Finally, there is no data on patients taking dupilumab who received the newly available COVID-19 vaccines. According to a recent study assessing tetanus and meningococcal vaccines following treatment with dupilumab, response correlates to non-live vaccines were apparently unaffected and vaccination was not associated with adverse clinical events. 23 We hypothesize that COVID-19 vaccines could similarly prove safe and immunogenic in adults with moderate-to-severe AD treated with dupilumab; however, these speculations require future testing in placebo-controlled trials.

During our observation period, over 240.000 cases of SARS-CoV-2 infection had been diagnosed in our country, accounting for over 34.000 deaths. 24 Even if withdrawal from therapy is commonly suggested in these cases, our decision to continue treatment was supported by the targeted anti-type 2 anti-inflammatory action of dupilumab. Continuation of therapy allowed all our patients to remain free from skin signs of active AD throughout the course of the lockdown period. Finally, we recommend that clinicians introduce surveys in their current medical practice to strengthen patient reliance on the attending physicians and to improve compliance with treatment, especially when personal interactions between patient and specialist are significantly limited.

In line with published studies on the tolerability of dupilumab in the COVID-19 era, our survey sustains the use of this drug in such setting. 25 The purpose of our study was to support the safety of dupilumab in a heterogenous population sample, including patients having significant comorbidities and being elderly.

Further reports together with more robust clinical data are required to elucidate the role of dupilumab and of other monoclonal antibodies in the setting of SARS-CoV-2 infection. 11 Such studies as proposed should encourage the use of biologics without reservation in the COVID-19 era and provide physicians with the solid evidence needed to guide their decisions in daily practice. 

Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II

Dupilumab: First Global Approval

Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2)

IL-4 and IL-13 signaling in allergic airway disease

Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma

Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial

COVID-19, asthma, and biological therapies: What we need to know

Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the COVID-19 pandemic

European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection and atopic dermatitis

No evidence of increased risk for Coronavirus Disease 2019 (COVID-19) in patients treated with Dupilumab for atopic dermatitis in a high-epidemic area

Assessing the risk of dupilumab use for atopic dermatitis during the COVID-19 pandemic

From atopic dermatitis to asthma: The atopic march

Targeting key proximal drivers of type 2 inflammation in disease

Mediators of Chronic Pruritus in Atopic Dermatitis: Getting the Itch Out?

Immunology of COVID-19: Current State of the Science

Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV. Williams BRG

Recent Insight into SARS-CoV2 Immunopathology and Rationale for Potential Treatment and Preventive Strategies in COVID-19

Safety of dupilumab in severe atopic dermatitis and infection of Covid-19: two case reports

Repurposing Dupilumab May Treat Advanced COVID-19 Patients With Severe Acute Respiratory Syndrome By Mitigating Cytokine Storm. OSF Prepr

Safety of dupilumab in atopic patients during COVID-19 outbreak

Belloni Fortina A. SARS-CoV-2 asymptomatic infection in a patient under treatment with dupilumab

COVID-19 in a patient with severe chronic rhinosinusitis with nasal polyps during therapy with dupilumab

Dupilumab does not affect correlates of vaccine-induced immunity: A randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis

Johns Hopkins Coronavirus Resource Center

Management of adult patients with severe atopic dermatitis treated with dupilumab during COVID-19 pandemic: A single-center real-life experience